AZ Targets Viral Oncolytics With Transgene Development Deal

AstraZeneca inks a deal with French firm Transgene to co-develop five armed oncolytic vaccinia virus candidates in an area that is hotting up for big pharma.

LightBulbs
AZ will provide five molecules for development • Source: Shutterstock

AstraZeneca PLC and immunotherapy specialist Transgene SA are to work together to develop armed oncolytic vaccinia virus candidates.

The companies announced on 2 May that they have signed a deal to collaborate on research, plus an option and exclusive license agreement to co-develop five candidates, which

More from R&D

More from Scrip